Summary

The oligonucleotide CDMO market is expected to reach USD 11.14 billion in 2031, up from USD 3.88 billion in 2026, at a CAGR of 23.5% over the forecast period. The oligonucleotide CDMO market is expanding as pharmaceutical and biotechnology companies increasingly outsource development and manufacturing to support growing oligonucleotide pipelines. Growing CDMO partnerships to enable scalability are driving demand for process development, synthesis, purification, analytical testing, and GMP manufacturing as programs advance toward clinical and commercial stages. Sponsors are increasingly seeking CDMOs with flexible capacity and integrated capabilities to support development through commercial manufacturing. However, the complexities of therapeutic oligonucleotide manufacturing remain a key restraint. Longer sequences, chemical modifications, and conjugation can increase synthesis and purification challenges. Maintaining consistent quality during scale-up also requires specialized equipment, validated processes, and skilled personnel. Consequently, CDMOs with scalable infrastructure and strong analytical capabilities are better positioned to support complex oligonucleotide programs. Antisense oligonucleotides segment is expected to grow at the highest CAGR during the forecast period The antisense oligonucleotide (ASO) segment is projected to grow at the highest CAGR in the oligonucleotide CDMO market, driven by expanding development of ASO-based therapeutics and increased outsourcing of manufacturing. ASO programs require specialized synthesis, purification, analytical testing, and GMP manufacturing capabilities. The advancement of ASO candidates through clinical development is increasing demand for scalable and reliable CDMO services. Rising molecular complexity is also prompting pharmaceutical and biotechnology companies to outsource manufacturing to specialized providers. These factors are expected to strengthen demand for oligonucleotide CDMO services supporting ASO development over the forecast period. Therapeutic applications segment to grow fastest The therapeutic applications segment is projected to grow at the highest CAGR in the oligonucleotide CDMO market, driven by expanding development of oligonucleotide-based therapeutics and increased outsourcing of manufacturing. Therapeutic programs require specialized services for synthesis, purification, analytical testing, and GMP manufacturing. The advancement of ASO, siRNA, and other oligonucleotide candidates through clinical development is increasing demand for scalable, regulatory-compliant manufacturing. Rising molecular complexity is further encouraging pharmaceutical and biotechnology companies to rely on specialized CDMOs. These factors are expected to strengthen demand for CDMO services supporting therapeutic applications during the forecast period. US is expected to grow at the highest CAGR during the forecast period The US is expected to post the highest CAGR in the oligonucleotide CDMO market, driven by a strong concentration of pharmaceutical and biotechnology companies with active oligonucleotide development pipelines. Established CDMO infrastructure and specialized capabilities in oligonucleotide synthesis, purification, analytical testing, and GMP manufacturing further support market growth. Rising demand for clinical and commercial manufacturing capacity is also strengthening outsourcing activity. Advancements in ASO, siRNA, and other oligonucleotide programs are driving demand for scalable manufacturing and specialized process development. These factors are expected to support continued expansion of the US oligonucleotide CDMO market over the forecast period. The primary interviews conducted for this report can be categorized as follows: • By Respondent: Supply Side – 70% and Demand Side– 30% • By Designation: Managers – 45%, CXOs and Directors – 30%, and Executives – 25% • By Region: North America – 40%, Europe – 25%, Asia Pacific – 25%, Latin America – 5%, the Middle East & Africa – 5% Bachem (Switzerland), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), WuXi AppTec (China), Maravai LifeSciences (US), Lonza (Switzerland), Eurofins Scientific (Luxembourg), Danaher Corporation (US), GenScript (US), Syngene International Limited (India), Ajinomoto Co., Inc. (Japan), EUROAPI (France), ST Pharm (South Korea), Kaneka Corporation (Japan), PolyPeptide Group (Switzerland), Aurigene Pharmaceutical Services Ltd. (India), BioSpring (Germany), Nippon Shokubai Co., Ltd. (Japan), LGC Biosearch Technologies (UK), Oligo Factory (US), Corden Pharma (Switzerland), Bio-Synthesis, Inc. (US), Microsynth (Switzerland), Synoligo Biotechnologies, Inc. (US), Hongene Biotech Corporation (China), Sylentis, S.A. (Spain), Creative Biogene (US), Nitto Avecia (US), and NJ Bio, Inc. (US) are key companies providing oligonucleotide CDMO services. Research Coverage This research report categorizes the oligonucleotide CDMO market by service type (contract manufacturing {commercial stage, clinical stage}, contract development, and other services {analytical testing, analytical method development & validation, and standalone fill-finish services}), by type (antisense oligonucleotides, small interfering RNA, and other oligonucleotides), by application (therapeutic applications, research applications, and diagnostic applications), by end user (pharmaceutical & biotechnology companies, diagnostic companies, and other end users), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The report’s scope encompasses detailed information on the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the oligonucleotide CDMO market. A comprehensive analysis of key industry players has been conducted to provide insights into their business overviews, service portfolios, key strategies, service expansions, acquisitions, and recent developments related to the oligonucleotide CDMO market. This report also includes a competitive analysis of emerging startups in the oligonucleotide CDMO industry ecosystem. Key Benefits of Buying the Report The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and provide information on key market drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: • Analysis of key drivers (Growing demand for pre-clinical-to-commercial oligo CDMOs, Increase in CDMO partnerships for scalability, Increasing focus on precision/personalized medicine), restraints (Complexities associated with therapeutic oligonucleotide manufacturing), opportunities (Increasing use of oligos in CRISPR-Cas9 applications, Growing demand for complex and modified oligonucleotides), and challenges (Lack of sustainable supply chain, Limited scalability of GMP oligonucleotide synthesis) influencing the market growth • Service Development/Innovation: Detailed insights into newly launched services and innovations in the oligonucleotide CDMO market • Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions • Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the oligonucleotide CDMO market Competitive Assessment: In-depth assessment of market shares, growth strategies, and services of leading players, Bachem (Switzerland), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), WuXi AppTec (China), and ST Pharm (South Korea), among others, for the oligonucleotide CDMO market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 31
1.1 STUDY OBJECTIVES 31
1.2 MARKET DEFINITION 31
1.2.1 INCLUSIONS & EXCLUSIONS 32
1.3 STUDY SCOPE 33
1.3.1 MARKET SEGMENTATION AND REGIONS COVERED 33
1.3.2 YEARS CONSIDERED 34
1.3.3 CURRENCY CONSIDERED 34
1.4 STAKEHOLDERS 34
1.5 SUMMARY OF CHANGES 35
2 EXECUTIVE SUMMARY 36
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 36
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 37
2.3 DISRUPTIVE TRENDS IN OLIGONUCLEOTIDES CDMO MARKET 38
2.4 HIGH-GROWTH SEGMENTS 39
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 40
3 PREMIUM INSIGHTS 41
3.1 OLIGONUCLEOTIDE CDMO MARKET OVERVIEW 41
3.2 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE 42
3.3 OLIGONUCLEOTIDE CDMO MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 43
3.4 OLIGONUCLEOTIDE CDMO MARKET SHARE, BY SERVICE TYPE, 2026 VS. 2031 44
4 MARKET OVERVIEW 45
4.1 INTRODUCTION 45
4.2 MARKET DYNAMICS 45
4.2.1 DRIVERS 46
4.2.1.1 Growing demand for Pre-Clinical-to-Commercial oligo CDMOs 46
4.2.1.2 Increase in CDMO partnerships for scalability 47
4.2.1.3 Increasing focus on precision/personalized medicine 47
4.2.2 RESTRAINTS 48
4.2.2.1 Complexities associated with therapeutic oligonucleotide manufacturing 48
4.2.3 OPPORTUNITIES 48
4.2.3.1 Increasing use of oligos in CRISPR-Cas9 applications 48
4.2.3.2 Expansion of oligonucleotide therapeutics into cardiometabolic and common chronic diseases 49
4.2.4 CHALLENGES 49
4.2.4.1 Lack of sustainable supply chain 49
4.2.4.2 Limited scalability of GMP oligonucleotide synthesis 50
4.3 UNMET NEEDS AND WHITE SPACES 50
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 51
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 51
5 INDUSTRY TRENDS 53
5.1 PORTER’S FIVE FORCES ANALYSIS 53
5.1.1 INTENSITY OF COMPETITIVE RIVALRY 54
5.1.2 BARGAINING POWER OF SUPPLIERS 54
5.1.3 BARGAINING POWER OF BUYERS 55
5.1.4 THREAT OF SUBSTITUTES 55
5.1.5 THREAT OF NEW ENTRANTS 55
5.2 MACROECONOMIC OUTLOOK 55
5.2.1 INTRODUCTION 55
5.2.2 GDP TRENDS AND FORECAST 56
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 57
5.2.4 TRENDS IN GLOBAL BIOTECH INDUSTRY 57
5.3 VALUE CHAIN ANALYSIS 58
5.4 ECOSYSTEM ANALYSIS 59
5.4.1 ROLE OF PLAYERS IN ECOSYSTEM 61
5.5 KEY CONFERENCES & EVENTS, 2026–2027 62
5.6 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 63
5.7 INVESTMENT & FUNDING SCENARIO 64
5.8 IMPACT OF 2025 US TARIFF ON OLIGONUCLEOTIDE CDMO MARKET 65
5.8.1 INTRODUCTION 65
5.8.2 KEY TARIFF RATES 65
5.8.3 PRICE IMPACT ANALYSIS 66
5.8.4 IMPACT ON COUNTRY/REGION 67
5.8.4.1 US 67
5.8.4.2 Europe 67
5.8.4.3 Asia Pacific 68
5.8.5 IMPACT ON END-USE INDUSTRIES 69
5.8.5.1 Pharmaceutical & Biotechnology Companies 69
5.8.5.2 Diagnostic companies 69
5.8.5.3 Other end users 70
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 71
6.1 TECHNOLOGY ANALYSIS 71
6.1.1 KEY TECHNOLOGIES 71
6.1.1.1 Process technologies 71
6.1.1.1.1 Solid-phase synthesis 71
6.1.1.1.2 Liquid-phase synthesis 72
6.1.1.1.3 Enzymatic phase synthesis 72
6.1.1.2 Purification, analysis, and quality control technologies 72
6.1.1.2.1 Affinity chromatography 72
6.1.1.2.2 Tangential flow filtration (tff) & ultrafiltration 73
6.1.2 COMPLEMENTARY TECHNOLOGIES 73
6.1.2.1 Polymerase chain reaction (PCR) 73
6.1.2.2 Next-generation sequencing (NGS) 74
6.1.2.3 Microarray technology/hybridization-based assays 74
6.1.3 ADJACENT TECHNOLOGIES 74
6.1.3.1 Galnac conjugation/Antibody–oligonucleotide conjugation 74
6.1.3.2 Lipid nanoparticle (LNP) encapsulation 75
6.2 TECHNOLOGY ROADMAP 75
6.3 FUTURE APPLICATIONS 76
6.4 IMPACT OF AI/GEN AI ON OLIGONUCLEOTIDE CDMO MARKET 76
6.4.1 TOP USE CASES AND MARKET POTENTIAL 77
6.4.2 BEST PRACTICES IN AI-ENABLED OLIGONUCLEOTIDE CDMO WORKFLOWS 78
6.4.3 CASE STUDIES OF AI IMPLEMENTATION IN OLIGONUCLEOTIDE CDMO MARKET 78
6.4.4 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 78
6.4.5 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED OLIGONUCLEOTIDE CDMO TECHNOLOGIES 79
7 SUSTAINABILITY AND REGULATORY LANDSCAPE 80
7.1 REGIONAL REGULATIONS AND COMPLIANCE 80
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
7.1.2 INDUSTRY STANDARDS 83
7.1.2.1 North America 83
7.1.2.2 Europe 83
7.1.2.3 Asia Pacific 84
7.1.2.4 Rest of the World 84
7.2 SUSTAINABILITY INITIATIVES 85
7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES 85
7.4 CERTIFICATIONS, LABELING, ECO-STANDARDS 86
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 88
8.1 DECISION-MAKING PROCESS 88
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 88
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 88
8.2.2 KEY BUYING CRITERIA, BY END USER 89
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 90
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 91
9 OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE 92
9.1 INTRODUCTION 93
9.2 CONTRACT MANUFACTURING 93
9.2.1 COMMERCIAL STAGE 97
9.2.1.1 Advancing oligonucleotide therapies and demand for reliable commercial-scale GMP supply are driving growth in commercial-stage services 97
9.2.2 CLINICAL STAGE 100
9.2.2.1 Advancing clinical pipelines and demand for specialized scalable manufacturing are driving growth in clinical-stage services 100
9.3 CONTRACT DEVELOPMENT 104
9.3.1 INCREASINGLY COMPLEX OLIGONUCLEOTIDE PIPELINES AND DEMAND FOR OPTIMIZED CLINICAL MANUFACTURING PROCESSES ARE DRIVING CONTRACT DEVELOPMENT GROWTH 104
9.4 OTHER SERVICES 107
9.4.1 INCREASING MOLECULAR COMPLEXITY AND DEMAND FOR INTEGRATED ANALYTICAL AND DRUG-PRODUCT SUPPORT ARE DRIVING GROWTH IN OTHER SERVICES 107
10 OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION 111
10.1 INTRODUCTION 112
10.2 THERAPEUTIC APPLICATIONS 112
10.2.1 EXPANDING THERAPEUTIC APPLICATIONS AND ADVANCING OLIGONUCLEOTIDE PIPELINES ARE DRIVING DEMAND FOR SPECIALIZED CDMO SERVICES. 112
10.3 RESEARCH APPLICATIONS 116
10.3.1 EXPANDING GENOMICS, SEQUENCING, CRISPR RESEARCH, AND OUTSOURCED CUSTOM SYNTHESIS DRIVE GROWTH 116
10.4 DIAGNOSTIC APPLICATIONS 119
10.4.1 EXPANDING MOLECULAR DIAGNOSTICS AND PRECISION ONCOLOGY DRIVE DEMAND FOR SPECIALIZED OLIGONUCLEOTIDE MANUFACTURING 119
11 OLIGONUCLEOTIDE CDMO MARKET, BY TYPE 123
11.1 INTRODUCTION 124
11.2 ANTISENSE OLIGONUCLEOTIDE (ASO) 124
11.2.1 ADVANCING ASO PIPELINES AND INCREASING DEMAND FOR SCALABLE GMP MANUFACTURING ARE DRIVING GROWTH 124
11.3 SMALL INTERFERING RNA (SIRNA) 128
11.3.1 EXPANDING SIRNA PIPELINES AND INCREASING DEMAND FOR SPECIALIZED GMP MANUFACTURING ARE DRIVING GROWTH IN THE MARKET. 128
11.4 OTHER OLIGONUCLEOTIDES 131
11.4.1 EXPANDING CRISPR AND TARGETED APTAMER APPLICATIONS DRIVE DEMAND FOR SPECIALIZED OLIGONUCLEOTIDE CDMO CAPABILITIES 131
12 OLIGONUCLEOTIDE CDMO MARKET, BY END USER 135
12.1 INTRODUCTION 136
12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 136
12.2.1 EXPANDING NUCLEIC ACID PIPELINES AND INCREASING OUTSOURCING DRIVE PHARMACEUTICAL AND BIOTECHNOLOGY DEMAND FOR CDMO SERVICES 136
12.3 DIAGNOSTIC COMPANIES 140
12.3.1 RISING MOLECULAR TESTING AND DEMAND FOR COMPLIANT CUSTOM OLIGOS DRIVE DIAGNOSTIC OUTSOURCING 140
12.4 OTHER END USERS 143
13 OLIGONUCLEOTIDE CDMO MARKET, BY REGION 147
13.1 INTRODUCTION 148
13.2 NORTH AMERICA 148
13.2.1 US 152
13.2.1.1 Expanding domestic GMP capacity and increasing outsourcing are driving US oligonucleotide CDMO growth. 152
13.2.2 CANADA 154
13.2.2.1 Integrated North American manufacturing networks and growing outsourcing demand are supporting Canada’s oligonucleotide CDMO market 154
13.3 EUROPE 156
13.3.1 GERMANY 158
13.3.1.1 Expanding GMP capacity and integrated oligonucleotide partnerships are driving Germany’s market growth 158
13.3.2 UK 160
13.3.2.1 Strengthening domestic nucleic-acid infrastructure and growing outsourcing demand are driving UK oligonucleotide CDMO growth 160
13.3.3 FRANCE 162
13.3.3.1 Strengthening nucleic-acid capabilities and growing outsourcing demand are driving France’s oligonucleotide CDMO market 162
13.3.4 ITALY 164
13.3.4.1 Specialized oligonucleotide infrastructure and growing demand for integrated development services are supporting Italy’s market growth 164
13.3.5 SPAIN 166
13.3.5.1 Expanding domestic manufacturing infrastructure and institutional support for therapeutic oligonucleotides are driving Spain’s market growth 166
13.3.6 REST OF EUROPE 168
13.4 ASIA PACIFIC 170
13.4.1 CHINA 173
13.4.1.1 Expanding integrated manufacturing capacity and strengthening domestic oligonucleotide supply chains are driving China’s market growth 173
13.4.2 JAPAN 176
13.4.2.1 Advanced manufacturing capabilities and rising demand for complex oligonucleotide therapeutics are driving Japan’s market growth 176
13.4.3 INDIA 178
13.4.3.1 Expanding GMP infrastructure and global outsourcing are driving India’s oligonucleotide CDMO market 178
13.4.4 AUSTRALIA 180
13.4.4.1 Expanding domestic manufacturing and growing biopharmaceutical outsourcing are supporting Australia’s oligonucleotide CDMO market 180
13.4.5 SOUTH KOREA 182
13.4.5.1 Synthetic biology, organoid-based screening, and AI-enabled discovery to support market growth 182
13.4.6 REST OF ASIA PACIFIC 184
13.5 LATIN AMERICA 186
13.5.1 BRAZIL 188
13.5.1.1 Infectious-disease research, shared protein-production infrastructure, and vaccine innovation to drive market 188
13.5.2 MEXICO 190
13.5.2.1 Nearshoring and expanding regional manufacturing capabilities are supporting Mexico’s oligonucleotide CDMO market 190
13.5.3 REST OF LATIN AMERICA 192
13.6 MIDDLE EAST 194
13.6.1 GCC 197
13.6.1.1 Saudi Arabia 199
13.6.1.1.1 Biotechnology localization and expanding genomic medicine capabilities are driving Saudi Arabia’s oligonucleotide CDMO market 199
13.6.1.2 UAE 201
13.6.1.2.1 Growing biopharmaceutical activity and need for localized advanced-therapy manufacturing are creating opportunities for UAE’s oligonucleotide CDMO services 201
13.6.1.3 Rest of GCC Countries 203
13.6.2 REST OF MIDDLE EAST 205
13.7 AFRICA 207
13.7.1 GROWING GENOMICS ACTIVITY AND LIMITED LOCAL MANUFACTURING CAPACITY ARE CREATING OPPORTUNITIES FOR OLIGONUCLEOTIDE CDMO SERVICES ACROSS AFRICA 207
14 COMPETITIVE LANDSCAPE 210
14.1 INTRODUCTION 210
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 210
14.2.1 KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE CDMO MARKET, 2023–2026 210
14.3 REVENUE ANALYSIS 212
14.4 MARKET SHARE ANALYSIS 213
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (OLIGONUCLEOTIDE CDMO MARKET), 2025 216
14.5.1 STARS 216
14.5.2 EMERGING LEADERS 216
14.5.3 PERVASIVE PLAYERS 217
14.5.4 PARTICIPANTS 217
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 223
14.6.1 PROGRESSIVE COMPANIES 223
14.6.2 RESPONSIVE COMPANIES 223
14.6.3 DYNAMIC COMPANIES 223
14.6.4 STARTING BLOCKS 223
14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 225
14.7 COMPETITIVE SCENARIO 226
14.7.1 PRODUCT APPROVALS 226
14.8 BRAND/PRODUCT COMPARATIVE ANALYSIS 230
14.9 COMPANY VALUATION AND FINANCIAL METRICS 231
14.9.1 COMPANY VALUATION AND FINANCIAL METRICS FOR OLIGONUCLEOTIDE CDMO PLAYERS 231
15 COMPANY PROFILES 232
15.1 KEY PLAYERS 232
15.1.1 BACHEM INC. 232
15.1.1.1 Business overview 232
15.1.1.2 Services offered 233
15.1.1.3 Recent developments 234
15.1.1.3.1 Product/Service launches 234
15.1.1.3.2 Expansions 234
15.1.1.4 MnM view 234
15.1.1.4.1 Key strengths 234
15.1.1.4.2 Strategic choices 235
15.1.1.4.3 Weaknesses and competitive threats 235
15.1.2 THERMO FISHER SCIENTIFIC INC. 236
15.1.2.1 Business overview 236
15.1.2.2 Services offered 237
15.1.2.3 Recent developments 238
15.1.2.3.1 Product/Service launches 238
15.1.2.3.2 Expansions 238
15.1.2.4 MnM view 238
15.1.2.4.1 Key strengths 238
15.1.2.4.2 Strategic choices 239
15.1.2.4.3 Weaknesses and competitive threats 239
15.1.3 AGILENT TECHNOLOGIES, INC. 240
15.1.3.1 Business overview 240
15.1.3.2 Services offered 241
15.1.3.3 Recent developments 242
15.1.3.3.1 Product/Service launches 242
15.1.3.3.2 Deals 242
15.1.3.3.3 Expansions 243
15.1.3.4 MnM view 243
15.1.3.4.1 Key strengths 243
15.1.3.4.2 Strategic choices 243
15.1.3.4.3 Weaknesses and competitive threats 243
15.1.4 WUXI APPTEC 244
15.1.4.1 Business overview 244
15.1.4.2 Services offered 245
15.1.4.3 Recent developments 246
15.1.4.3.1 Expansions 246
15.1.4.4 MnM view 246
15.1.4.4.1 Key strengths/Right to win 246
15.1.4.4.2 Strategic choices made 246
15.1.4.4.3 Weaknesses and competitive threats 246
15.1.5 MARAVAI LIFESCIENCES 247
15.1.5.1 Business overview 247
15.1.5.2 Services offered 248
15.1.5.3 Recent developments 249
15.1.5.3.1 Deals 249
15.1.6 LONZA 250
15.1.6.1 Business overview 250
15.1.6.2 Services offered 251
15.1.6.3 Recent developments 252
15.1.6.3.1 Deals 252
15.1.6.3.2 Expansions 252
15.1.7 EUROFINS SCIENTIFIC 253
15.1.7.1 Business overview 253
15.1.7.2 Services offered 254
15.1.7.3 Recent developments 255
15.1.7.3.1 Expansions 255
15.1.8 DANAHER CORPORATION 256
15.1.8.1 Business overview 256
15.1.8.2 Services offered 257
15.1.8.3 Recent developments 258
15.1.8.3.1 Expansions 258
15.1.8.3.2 Other Developments 258
15.1.9 GENSCRIPT 259
15.1.9.1 Business overview 259
15.1.9.2 Services offered 260
15.1.9.3 Recent developments 261
15.1.9.3.1 Expansions 261
15.1.10 SYNGENE INTERNATIONAL LIMITED 262
15.1.10.1 Business overview 262
15.1.10.2 Services offered 263
15.1.10.3 Recent developments 264
15.1.10.3.1 Product/Service launches 264
15.1.10.3.2 Expansions 264
15.1.11 EUROAPI 265
15.1.11.1 Business overview 265
15.1.11.2 Services offered 266
15.1.11.3 Recent developments 267
15.1.11.3.1 Deals 267
15.1.11.3.2 Expansions 267
15.1.12 AJINOMOTO CO., INC. 268
15.1.12.1 Business overview 268
15.1.12.2 Services offered 269
15.1.12.3 Recent developments 269
15.1.12.3.1 Expansions 269
15.1.12.3.2 Deals 269
15.1.13 ST PHARM 270
15.1.13.1 Business overview 270
15.1.13.2 Services offered 271
15.1.13.3 Recent developments 271
15.1.13.3.1 Expansions 271
15.1.13.3.2 Deals 271
15.1.13.4 MnM view 272
15.1.13.4.1 Key strengths 272
15.1.13.4.2 Strategic choices 272
15.1.13.4.3 Weaknesses and competitive threats 272
15.1.14 KANEKA CORPORATION 273
15.1.14.1 Business overview 273
15.1.14.2 Services offered 275
15.1.15 POLYPEPTIDE GROUP 276
15.1.15.1 Business overview 276
15.1.15.2 Services offered 277
15.1.15.3 Recent developments 277
15.1.15.3.1 Expansions 277
15.1.16 AURIGENE PHARMACEUTICAL SERVICES LTD. 278
15.1.16.1 Business overview 278
15.1.16.2 Services offered 278
15.1.17 BIOSPRING 279
15.1.17.1 Business overview 279
15.1.17.2 Services offered 279
15.1.17.3 Recent developments 280
15.1.17.3.1 Service approvals 280
15.1.17.3.2 Expansions 280
15.1.18 NIPPON SHOKUBAI CO., LTD. 281
15.1.18.1 Business overview 281
15.1.18.2 Services offered 282
15.1.18.3 Recent developments 283
15.1.18.3.1 Service launch 283
15.1.18.3.2 Expansions 283
15.1.19 LGC BIOSEARCH TECHNOLOGIES 284
15.1.19.1 Business overview 284
15.1.19.2 Services offered 285
15.1.19.3 Recent developments 286
15.1.19.3.1 Service launch 286
15.1.19.3.2 Deals 286
15.1.19.3.3 Expansions 287
15.2 OTHER PLAYERS 288
15.2.1 OLIGO FACTORY 288
15.2.2 CORDEN PHARMA 288
15.2.3 BIO-SYNTHESIS, INC. 289
15.2.4 MICROSYNTH 289
15.2.5 SYNOLIGO BIOTECHNOLOGIES, INC. 290
15.2.6 HONGENE BIOTECH CORPORATION 290
15.2.7 SYLENTIS, S.A. 291
15.2.8 CREATIVE BIOGENE 291
15.2.9 NITTO AVECIA 292
15.2.10 NJ BIO, INC. 293
16 RESEARCH METHODOLOGY 294
16.1 RESEARCH DATA 294
16.1.1 SECONDARY DATA 295
16.1.1.1 Key data from secondary sources 295
16.1.2 PRIMARY DATA 296
16.1.2.1 Key data from primary sources 296
16.1.2.2 Key primary participants 296
16.1.2.3 Breakdown of primary interviews 297
16.1.2.4 Key industry insights 298
16.2 MARKET SIZE ESTIMATION 299
16.2.1 GLOBAL OLIGONUCLEOTIDE CDMO MARKET ESTIMATION, 2025 299
16.2.2 SEGMENTAL MARKET SIZE ESTIMATION 302
16.3 MARKET GROWTH RATE PROJECTIONS 303
16.4 DATA TRIANGULATION 305
16.5 FACTOR ANALYSIS 306
16.6 RESEARCH ASSUMPTIONS 306
16.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT 307
17 APPENDIX 308
17.1 DISCUSSION GUIDE 308
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 312
17.3 CUSTOMIZATION OPTIONS 314
17.4 RELATED REPORTS 314
17.5 AUTHOR DETAILS 315

ページTOPに戻る

List of Tables/Graphs

TABLE 1 OLIGONUCLEOTIDE CDMO MARKET: INCLUSIONS AND EXCLUSIONS 32.
TABLE 2 OLIGONUCLEOTIDE SYNTHESIS MARKET: IMPACT ANALYSIS 46.
TABLE 3 OLIGONUCLEOTIDE CDMO MARKET: PORTER’S FIVE FORCES 53.
TABLE 4 OLIGONUCLEOTIDE CDMO MARKET: ROLE OF PLAYERS IN ECOSYSTEM 61.
TABLE 5 OLIGONUCLEOTIDE CDMO MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2026–JUNE 2027 62.
TABLE 6 RECIPROCAL TARIFF RATES ADJUSTED BY US 65.
TABLE 7 CASE STUDIES OF AI IMPLEMENTATION IN OLIGONUCLEOTIDE CDMO MARKET 78.
TABLE 8 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED OLIGONUCLEOTIDE CDMO TECHNOLOGIES IN OLIGONUCLEOTIDE CDMO MARKET 79.
TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 80.
TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81.
TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81.
TABLE 12 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82.
TABLE 13 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 82.
TABLE 14 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY SERVICE TYPE 89.
TABLE 15 KEY BUYING CRITERIA, BY END USER 89.
TABLE 16 OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 93.
TABLE 17 OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING,
BY TYPE, 2024–2031 (USD MILLION) 94.
TABLE 18 OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING,
BY REGION, 2024–2031 (USD MILLION) 94.
TABLE 19 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION) 94.
TABLE 20 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION) 95.
TABLE 21 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION) 95.
TABLE 22 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION) 96.
TABLE 23 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY REGION, 2024–2031 (USD MILLION) 96.
TABLE 24 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY REGION, 2024–2031 (USD MILLION) 96.
TABLE 25 OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY REGION, 2024–2031 (USD MILLION) 97.
TABLE 26 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION) 98.
TABLE 27 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION) 98.
TABLE 28 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION) 99.
TABLE 29 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION) 99.
TABLE 30 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY REGION, 2024–2031 (USD MILLION) 100.
TABLE 31 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY REGION, 2024–2031 (USD MILLION) 100.
TABLE 32 OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY REGION, 2024–2031 (USD MILLION) 101.
TABLE 33 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION) 101.
TABLE 34 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION) 102.
TABLE 35 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION) 102.
TABLE 36 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION) 103.
TABLE 37 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY REGION, 2024–2031 (USD MILLION) 103.
TABLE 38 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY REGION, 2024–2031 (USD MILLION) 103.
TABLE 39 OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION) 104.
TABLE 40 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 105.
TABLE 41 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 105.
TABLE 42 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 106.
TABLE 43 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 106.
TABLE 44 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION) 107.
TABLE 45 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION) 107.
TABLE 46 OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES, BY REGION,
2024–2031 (USD MILLION) 108.
TABLE 47 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES,
BY COUNTRY, 2024–2031 (USD MILLION) 108.
TABLE 48 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES,
BY COUNTRY, 2024–2031 (USD MILLION) 109.
TABLE 49 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES,
BY COUNTRY, 2024–2031 (USD MILLION) 109.
TABLE 50 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES,
BY COUNTRY, 2024–2031 (USD MILLION) 110.
TABLE 51 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES,
BY REGION, 2024–2031 (USD MILLION) 110.
TABLE 52 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES,
BY REGION, 2024–2031 (USD MILLION) 110.
TABLE 53 OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 112.
TABLE 54 OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 113.
TABLE 55 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 113.
TABLE 56 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 114.
TABLE 57 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 114.
TABLE 58 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 115.
TABLE 59 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 115.
TABLE 60 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 115.
TABLE 61 OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS,
BY REGION, 2024–2031 (USD MILLION) 116.
TABLE 62 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 117.
TABLE 63 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 117.
TABLE 64 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 118.
TABLE 65 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 118.
TABLE 66 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 119.
TABLE 67 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 119.
TABLE 68 OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 120.
TABLE 69 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 120.
TABLE 70 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 121.
TABLE 71 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 121.
TABLE 72 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 122.
TABLE 73 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 122.
TABLE 74 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 122.
TABLE 75 OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION) 124.
TABLE 76 OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY REGION,
2024–2031 (USD MILLION) 125.
TABLE 77 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR ASO,
BY COUNTRY, 2024–2031 (USD MILLION) 125.
TABLE 78 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY COUNTRY,
2024–2031 (USD MILLION) 126.
TABLE 79 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY COUNTRY,
2024–2031 (USD MILLION) 126.
TABLE 80 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY COUNTRY, 2024–2031 (USD MILLION) 127.
TABLE 81 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY REGION,
2024–2031 (USD MILLION) 127.
TABLE 82 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY REGION,
2024–2031 (USD MILLION) 127.
TABLE 83 OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY REGION,
2024–2031 (USD MILLION) 128.
TABLE 84 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY, 2024–2031 (USD MILLION) 129.
TABLE 85 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY,
2024–2031 (USD MILLION) 129.
TABLE 86 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY, 2024–2031 (USD MILLION) 130.
TABLE 87 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY, 2024–2031 (USD MILLION) 130.
TABLE 88 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY REGION,
2024–2031 (USD MILLION) 131.
TABLE 89 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA,
BY REGION, 2024–2031 (USD MILLION) 131.
TABLE 90 OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY REGION,
2024–2031 (USD MILLION) 132.
TABLE 91 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY COUNTRY, 2024–2031 (USD MILLION) 132.
TABLE 92 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY COUNTRY,
2024–2031 (USD MILLION) 133.
TABLE 93 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY COUNTRY, 2024–2031 (USD MILLION) 133.
TABLE 94 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY COUNTRY, 2024–2031 (USD MILLION) 134.
TABLE 95 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS,
BY REGION, 2024–2031 (USD MILLION) 134.
TABLE 96 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS,
BY REGION, 2024–2031 (USD MILLION) 134.
TABLE 97 OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION) 136.
TABLE 98 OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 137.
TABLE 99 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 137.
TABLE 100 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 138.
TABLE 101 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 138.
TABLE 102 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 139.
TABLE 103 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 139.
TABLE 104 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 139.
TABLE 105 OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY REGION, 2024–2031 (USD MILLION) 140.
TABLE 106 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 141.
TABLE 107 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES,
BY COUNTRY, 2024–2031 (USD MILLION) 141.
TABLE 108 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 142.
TABLE 109 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 142.
TABLE 110 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY REGION, 2024–2031 (USD MILLION) 143.
TABLE 111 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY REGION, 2024–2031 (USD MILLION) 143.
TABLE 112 OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS, BY REGION,
2024–2031 (USD MILLION) 144.
TABLE 113 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2031 (USD MILLION) 144.
TABLE 114 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2031 (USD MILLION) 145.
TABLE 115 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2031 (USD MILLION) 145.
TABLE 116 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2031 (USD MILLION) 146.
TABLE 117 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS,
BY REGION, 2024–2031 (USD MILLION) 146.
TABLE 118 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS,
BY REGION, 2024–2031 (USD MILLION) 146.
TABLE 119 OLIGONUCLEOTIDE CDMO MARKET, BY REGION, 2024–2031 (USD MILLION) 148.
TABLE 120 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 149.
TABLE 121 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 150.
TABLE 122 NORTH AMERICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 150.
TABLE 123 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2024–2031 (USD MILLION) 150.
TABLE 124 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 151.
TABLE 125 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 151.
TABLE 126 US: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 152.
TABLE 127 US: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 152.
TABLE 128 US: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION) 153.
TABLE 129 US: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 153.
TABLE 130 US: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 153.
TABLE 131 CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 154.
TABLE 132 CANADA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 155.
TABLE 133 CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2024–2031 (USD MILLION) 155.
TABLE 134 CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 155.
TABLE 135 CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 156.
TABLE 136 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 156.
TABLE 137 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 157.
TABLE 138 EUROPE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 157.
TABLE 139 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2024–2031 (USD MILLION) 157.
TABLE 140 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 158.
TABLE 141 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 158.
TABLE 142 GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 159.
TABLE 143 GERMANY: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 159.
TABLE 144 GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2024–2031 (USD MILLION) 159.
TABLE 145 GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 160.
TABLE 146 GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 160.
TABLE 147 UK: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 161.
TABLE 148 UK: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 161.
TABLE 149 UK: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION) 161.
TABLE 150 UK: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 162.
TABLE 151 UK: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 162.
TABLE 152 FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 163.
TABLE 153 FRANCE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 163.
TABLE 154 FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION) 163.
TABLE 155 FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 164.
TABLE 156 FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 164.
TABLE 157 ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 165.
TABLE 158 ITALY: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 165.
TABLE 159 ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION) 165.
TABLE 160 ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 166.
TABLE 161 ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 166.
TABLE 162 SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 167.
TABLE 163 SPAIN: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 167.
TABLE 164 SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION) 167.
TABLE 165 SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 168.
TABLE 166 SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 168.
TABLE 167 REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 169.
TABLE 168 REST OF EUROPE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 169.
TABLE 169 REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2024–2031 (USD MILLION) 169.
TABLE 170 REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 170.
TABLE 171 REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 170.
TABLE 172 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 171.
TABLE 173 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 172.
TABLE 174 ASIA PACIFIC: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 172.
TABLE 175 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2024–2031 (USD MILLION) 172.
TABLE 176 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 173.
TABLE 177 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 173.
TABLE 178 CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 174.
TABLE 179 CHINA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 174.
TABLE 180 CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION) 175.
TABLE 181 CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 175.
TABLE 182 CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 175.
TABLE 183 JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 176.
TABLE 184 JAPAN: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 176.
TABLE 185 JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION) 177.
TABLE 186 JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 177.
TABLE 187 JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 177.
TABLE 188 INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 178.
TABLE 189 INDIA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 178.
TABLE 190 INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION) 179.
TABLE 191 INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 179.
TABLE 192 INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 179.
TABLE 193 AUSTRALIA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 180.
TABLE 194 AUSTRALIA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 180.
TABLE 195 AUSTRALIA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2024–2031 (USD MILLION) 181.
TABLE 196 AUSTRALIA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 181.
TABLE 197 AUSTRALIA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 181.
TABLE 198 SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 182.
TABLE 199 SOUTH KOREA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 182.
TABLE 200 SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2024–2031 (USD MILLION) 183.
TABLE 201 SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 183.
TABLE 202 SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 183.
TABLE 203 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 184.
TABLE 204 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 184.
TABLE 205 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2024–2031 (USD MILLION) 185.
TABLE 206 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 185.
TABLE 207 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 185.
TABLE 208 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 186.
TABLE 209 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 186.
TABLE 210 LATIN AMERICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 187.
TABLE 211 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2024–2031 (USD MILLION) 187.
TABLE 212 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 187.
TABLE 213 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 188.
TABLE 214 BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 189.
TABLE 215 BRAZIL: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 189.
TABLE 216 BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION) 189.
TABLE 217 BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 190.
TABLE 218 BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 190.
TABLE 219 MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 191.
TABLE 220 MEXICO: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 191.
TABLE 221 MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION) 191.
TABLE 222 MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 192.
TABLE 223 MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 192.
TABLE 224 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 193.
TABLE 225 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 193.
TABLE 226 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET,
BY TYPE, 2024–2031 (USD MILLION) 193.
TABLE 227 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 194.
TABLE 228 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET,
BY END USER, 2024–2031 (USD MILLION) 194.
TABLE 229 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 195.
TABLE 230 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 195.
TABLE 231 MIDDLE EAST: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 195.
TABLE 232 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2024–2031 (USD MILLION) 196.
TABLE 233 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 196.
TABLE 234 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 196.
TABLE 235 GCC: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 197.
TABLE 236 GCC: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 197.
TABLE 237 GCC: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 198.
TABLE 238 GCC: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION) 198.
TABLE 239 GCC: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 198.
TABLE 240 GCC: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 199.
TABLE 241 SAUDI ARABIA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 199.
TABLE 242 SAUDI ARABIA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 200.
TABLE 243 SAUDI ARABIA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2024–2031 (USD MILLION) 200.
TABLE 244 SAUDI ARABIA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 200.
TABLE 245 SAUDI ARABIA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 201.
TABLE 246 UAE: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 201.
TABLE 247 UAE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 202.
TABLE 248 UAE: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION) 202.
TABLE 249 UAE: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 202.
TABLE 250 UAE: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 203.
TABLE 251 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 203.
TABLE 252 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 204.
TABLE 253 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET,
BY TYPE, 2024–2031 (USD MILLION) 204.
TABLE 254 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 204.
TABLE 255 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET,
BY END USER, 2024–2031 (USD MILLION) 205.
TABLE 256 REST OF MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 205.
TABLE 257 REST OF MIDDLE EAST: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 206.
TABLE 258 REST OF MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2024–2031 (USD MILLION) 206.
TABLE 259 REST OF MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 206.
TABLE 260 REST OF MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 207.
TABLE 261 AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 208.
TABLE 262 AFRICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 208.
TABLE 263 AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION) 208.
TABLE 264 AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 209.
TABLE 265 AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2024–2031 (USD MILLION) 209.
TABLE 266 KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE CDMO MARKET, 2023–2026 211.
TABLE 267 OLIGONUCLEOTIDE CDMO MARKET: DEGREE OF COMPETITION 214.
TABLE 268 OLIGONUCLEOTIDE CDMO MARKET: REGIONAL FOOTPRINT 219.
TABLE 269 OLIGONUCLEOTIDE CDMO MARKET: SERVICE TYPE FOOTPRINT 220.
TABLE 270 OLIGONUCLEOTIDE CDMO MARKET: TYPE FOOTPRINT 221.
TABLE 271 OLIGONUCLEOTIDE CDMO MARKET: APPLICATION FOOTPRINT 222.
TABLE 272 DETAILED LIST OF KEY STARTUPS/SMES 225.
TABLE 273 COMPETITIVE BENCHMARKING OF STARTUPS/SMES 226.
TABLE 274 OLIGONUCLEOTIDE CDMO MARKET: SERVICE LAUNCHES,
JANUARY 2023–JULY 2026 226.
TABLE 275 OLIGONUCLEOTIDE CDMO MARKET: DEALS, JANUARY 2023-JULY 2026 227.
TABLE 276 OLIGONUCLEOTIDE CDMO MARKET: EXPANSIONS, JANUARY 2023-JULY 2026 229.
TABLE 277 BACHEM INC.: COMPANY OVERVIEW 232.
TABLE 278 BACHEM INC.: SERVICES OFFERED 233.
TABLE 279 BACHEM INC.: SERVICE LAUNCHES, JANUARY 2023–JULY 2026 234.
TABLE 280 BACHEM INC.: EXPANSIONS, JANUARY 2023–JULY 2026 234.
TABLE 281 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 236.
TABLE 282 THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED 237.
TABLE 283 THERMO FISHER SCIENTIFIC INC.: SERVICE LAUNCHES,
JANUARY 2023–JULY 2026 238.
TABLE 284 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2023–JULY 2026 238.
TABLE 285 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 240.
TABLE 286 AGILENT TECHNOLOGIES, INC.: SERVICES OFFERED 241.
TABLE 287 AGILENT TECHNOLOGIES, INC.: SERVICE LAUNCHES, JANUARY 2023–JULY 2026 242.
TABLE 288 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023–JULY 2026 242.
TABLE 289 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2023–JULY 2026 243.
TABLE 290 WUXI APPTEC: COMPANY OVERVIEW 244.
TABLE 291 WUXI APPTEC: SERVICES OFFERED 245.
TABLE 292 WUXI APPTEC: EXPANSIONS, JANUARY 2023–JULY 2026 246.
TABLE 293 MARAVAI LIFESCIENCES: COMPANY OVERVIEW 247.
TABLE 294 MARAVAI LIFESCIENCES: SERVICES OFFERED 248.
TABLE 295 MARAVAI LIFESCIENCES: DEALS, JANUARY 2023–JULY 2026 249.
TABLE 296 LONZA: COMPANY OVERVIEW 250.
TABLE 297 LONZA: SERVICES OFFERED 251.
TABLE 298 LONZA: DEALS, JANUARY 2023–JULY 2026 252.
TABLE 299 LONZA: EXPANSIONS, JANUARY 2023–JULY 2026 252.
TABLE 300 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 253.
TABLE 301 EUROFINS SCIENTIFIC: SERVICES OFFERED 254.
TABLE 302 EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2023–JULY 2026 255.
TABLE 303 DANAHER CORPORATION: COMPANY OVERVIEW 256.
TABLE 304 DANAHER CORPORATION: SERVICES OFFERED 257.
TABLE 305 DANAHER CORPORATION: EXPANSIONS, JANUARY 2023–JULY 2026 258.
TABLE 306 DANAHER CORPORATION: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026 258.
TABLE 307 GENSCRIPT: COMPANY OVERVIEW 259.
TABLE 308 GENSCRIPT: SERVICES OFFERED 260.
TABLE 309 GENSCRIPT: EXPANSIONS, JANUARY 2023–JULY 2026 261.
TABLE 310 SYNGENE INTERNATIONAL LIMITED: COMPANY OVERVIEW 262.
TABLE 311 SYNGENE INTERNATIONAL LIMITED: SERVICES OFFERED 263.
TABLE 312 SYNGENE INTERNATIONAL LIMITED: SERVICE LAUNCHES,
JANUARY 2023–JULY 2026 264.
TABLE 313 SYNGENE INTERNATIONAL LIMITED: EXPANSIONS, JANUARY 2023–JULY 2026 264.
TABLE 314 EUROAPI: COMPANY OVERVIEW 265.
TABLE 315 EUROAPI: SERVICES OFFERED 266.
TABLE 316 EUROAPI: DEALS, JANUARY 2023–JULY 2026 267.
TABLE 317 EUROAPI: EXPANSIONS, JANUARY 2023–JULY 2026 267.
TABLE 318 AJINOMOTO CO., INC.: COMPANY OVERVIEW 268.
TABLE 319 AJINOMOTO CO., INC.: SERVICES OFFERED 269.
TABLE 320 AJINOMOTO CO., INC.: EXPANSIONS, JANUARY 2023–JULY 2026 269.
TABLE 321 AJINOMOTO CO., INC.: DEALS, JANUARY 2023–JULY 2026 269.
TABLE 322 ST PHARM: COMPANY OVERVIEW 270.
TABLE 323 ST PHARM: SERVICES OFFERED 271.
TABLE 324 ST PHARM: EXPANSIONS, JANUARY 2023–JULY 2026 271.
TABLE 325 ST PHARM: DEALS, JANUARY 2023–JULY 2026 271.
TABLE 326 KANEKA CORPORATION: COMPANY OVERVIEW 273.
TABLE 327 KANEKA CORPORATION: SERVICES OFFERED 275.
TABLE 328 POLYPEPTIDE GROUP: COMPANY OVERVIEW 276.
TABLE 329 POLYPEPTIDE GROUP: SERVICES OFFERED 277.
TABLE 330 POLYPEPTIDE GROUP: EXPANSIONS, JANUARY 2023–JULY 2026 277.
TABLE 331 AURIGENE PHARMACEUTICAL SERVICES LTD.: COMPANY OVERVIEW 278.
TABLE 332 AURIGENE PHARMACEUTICAL SERVICES LTD.: SERVICES OFFERED 278.
TABLE 333 BIOSPRING: COMPANY OVERVIEW 279.
TABLE 334 BIOSPRING: SERVICES OFFERED 279.
TABLE 335 BIOSPRING: SERVICE APPROVALS, JANUARY 2023–JULY 2026 280.
TABLE 336 BIOSPRING: EXPANSIONS, JANUARY 2023–JULY 2026 280.
TABLE 337 NIPPON SHOKUBAI CO., LTD.: COMPANY OVERVIEW 281.
TABLE 338 NIPPON SHOKUBAI CO., LTD.: SERVICES OFFERED 282.
TABLE 339 NIPPON SHOKUBAI CO., LTD.: SERVICE LAUNCH, JANUARY 2023–JULY 2026 283.
TABLE 340 NIPPON SHOKUBAI CO., LTD.: EXPANSIONS, JANUARY 2023–JULY 2026 283.
TABLE 341 LGC BIOSEARCH TECHNOLOGIES: COMPANY OVERVIEW 284.
TABLE 342 LGC BIOS